

**Potential Risks of Drug Reaction with Eosino philia and Systemic Symptoms (DRESS)
In the Use of Piperacillin (Single or Combination with Tazobactam)**

Piperacillin is an antibiotic that can be used singly or in combination with products that increase activity (tazobactam). Both products are administered through intravenous or intramuscular and are used for the treatment of various types of infections.

On February 24, 2016, Health-Canada undertook a safety review to evaluate the potential link between antibiotic drugs which is a combination of piperacillin and tazobactam or single piperacillin with Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Health Canada identified 17 cases of DRESS associated with a combination of the drug piperacillin and tazobactam. One case led to death, although a direct role for a drug combination could not be established during an existing health problem. In 10 cases, the patients recovered after discontinuing combination therapy with or without report of additional treatment, while the other 6 cases could not be assessed further because the information on the report was incomplete. Based on this, Health Canada updates product information for combination drugs of piperacillin and tazobactam with DRESS risk warning and incorporates potential adverse drug reaction of DRESS for single piperacillin.

DRESS describes a rare but a potentially life-threatening collection of adverse drug reaction for the drug, characterized by fever, severe skin rash, enlarged lymph nodes, hepatitis, leukocytosis with eosinophilia.

There is no information of DRESS risk on the use of piperacillin-tazobactam at the websites of other authorities such as the US-FDA, EMA, and TGA (Australia).

NADFC issued safety alerts to healthcare professionals in order to increase awareness in the use of piperacillin (single or combination with tazobactam). In case of adverse reaction in drug use, health professionals may report the incident to NADFC by using the yellow form or may also report online at <http://e-meso.pom.go.id>. NADFC will continuously monitor the aspect of drug safety in order to provide optimal protection to the public health, and as an effort to ensure the drug safety in Indonesia.